Stephanie A. Moquin, Suresh B. Lakshminarayana, Kamal Kumar Balavenkatraman, Hilmar Schiller, Allison Claas, Barun Bhhatarai, Ioannis Loisios-Konstantinidis, Katarina Vulic, Chaitanya Kurhade, Birte K. Kalveram, John Yun-Chung Chen, Jing Zou, Xuping Xie, Laura Tandeske, Dustin Dovala, Elizabeth Ornelas, Mark S. Knapp, Daniel Fuller, Zachary Nguyen, David T. Barkan, Lidiya Bebrevska, S. Kirk Wright, Scott A. Busby, Johanne Blais, Pei-Yong Shi, Suzanne Gaudet, Renee Bergeron, Hannah Yu, Julia Zack, Christopher Sarko, Feng Gu, James E. Bradner, John A. Tallarico, Thierry T. Diagana & Julien P. N. Papillon
npj Drug Discov. 2, 28 (2025).
https://doi.org/10.1038/s44386-025-00030-5
EGT710 is an orally bioavailable non-peptidomimetic reversible covalent coronavirus main protease (Mpro) inhibitor with low nM cellular activity against SARS-CoV-2. Twice daily dosing of 10 mg/kg of EGT710 decreased lung viral load in a mouse model of SARS-CoV-2 infection to below the limit of detection. Resistance selection resulted in the emergence of several Mpro mutations, with recombinant viruses containing L50F + E166A substitutions showing the largest shift in potency. Development of a viral kinetics model using viremia data from clinical trials, along with a human physiologically based pharmacokinetic model, predicted efficacy in humans with once daily oral doses of >360 mg. EGT710 displays favorable pharmacokinetic properties and an acceptable in vitro and in vivo safety profile, with human exposures at the recommended clinical dose of 600 mg predicted to be below the no adverse effect level in preclinical toxicology studies. Together, EGT710 has a promising preclinical profile and has completed a Phase I study.
